{"schema_version":"secwatch.filing_event.v1","accession":"0001453687-25-000123","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.444672+00:00","generated_at":"2026-05-16T20:18:17.241522+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"confidence":"high","headline":"Cartesian reports 100% LLDAS response in Phase 2 SLE; expands Descartes-08 into myositis","bullets":["100% LLDAS response at Month 3 (n=3) in Phase 2 SLE trial; 2 of 3 achieved DORIS remission.","No CRS or ICANS observed; outpatient administration without lymphodepleting chemotherapy.","Plans to pause SLE and Descartes-15 (multiple myeloma) to prioritize MG Phase 3 and myositis.","Myositis seamless adaptive Phase 2 trial expected to start 1H26; IND filing by end 2025.","Cash runway extended to mid-2027 supporting MG Phase 3 and myositis trial initiation."],"urls":{"canonical":"https://secwatch.observer/filing/0001453687-25-000123","json":"https://secwatch.observer/filing/0001453687-25-000123.json","markdown":"https://secwatch.observer/filing/0001453687-25-000123.md","text":"https://secwatch.observer/filing/0001453687-25-000123.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000145368725000123/0001453687-25-000123-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000145368725000123/rnac-20251113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:18:17.241522+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}